Highlights Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-28 EDT			5-day change	1st Jan Change
80.4 ^SEK	+0.12%		+4.15%	+101.00%

05-23	Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	CI
05-20	Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	05-23	CI
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	04-22	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-14	CI
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	02-12	CI
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage	11-21	CI
Xspray Pharma AB Through HyNap? technology Announces Results from Drug Interaction Studies	11-08	CI
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Xspray Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
US FDA Requests More Data from Xspray Pharma for Dasynoc Drug Candidate; Shares Fall 7%	23-07-11	MT
Xspray Pharma AB Receives Request for Additional Information Concerning Dasynoc from FDA	23-07-11	CI
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Xspray Pharma AB Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc for the Treatment of Chronic Myeloid Leukemia and Acute Lymphatic Leukemia	23-02-23	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB's Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia	22-11-30	CI
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Xspray Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
Xspray Pharma Shares Up 10% on US FDA's Orphan Drug Tag for Blood Cancer Therapy	22-06-17	MT
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Highlights

Filters